EGFR tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC) patients with activating <i>EGFR</i> mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.